Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.

Despite the development of novel drugs, the prospects for many patients with acute myeloid leukemia (AML) remain dismal. This study reveals that the selective inhibitor of RNA polymerase I (Pol I) transcription, CX-5461, effectively treats aggressive AML, including mixed-lineage leukemia-driven AML, and outperforms standard chemotherapies. In addition to the previously characterized mechanism of action of CX-5461 (ie, the induction of p53-dependent apoptotic cell death), the inhibition of Pol I transcription also demonstrates potent efficacy in p53null AML in vivo. This significant survival advantage in both p53WT and p53null leukemic mice treated with CX-5461 is associated with activation of the checkpoint kinases 1/2, an aberrant G2/M cell-cycle progression and induction of myeloid differentiation of the leukemic blasts. The ability to target the leukemic-initiating cell population is thought to be essential for lasting therapeutic benefit. Most strikingly, the acute inhibition of Pol I transcription reduces both the leukemic granulocyte-macrophage progenitor and leukemia-initiating cell (LIC) populations, and suppresses their clonogenic capacity. This suggests that dysregulated Pol I transcription is essential for the maintenance of their leukemia-initiating potential. Together, these findings demonstrate the therapeutic utility of this new class of inhibitors to treat highly aggressive AML by targeting LICs.

[1]  T. J. Lindell,et al.  Inhibition of nucleoplasmic transcription and the translation of rapidly labeled nuclear proteins by low concentrations of actinomycin D in vivo. Proposed role of messenger RNA in ribosomal RNA transcription. , 1978, Biochemistry.

[2]  A. Shilatifard,et al.  Multiple Mixed Lineage Leukemia (MLL) Fusion Proteins Suppress p53-mediated Response to DNA Damage* , 2005, Journal of Biological Chemistry.

[3]  T. Golub,et al.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9 , 2006, Nature.

[4]  M. Cleary,et al.  Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. , 2006, Cancer cell.

[5]  L. Möllgård,et al.  Mutated and non‐mutated TP53 as targets in the treatment of leukaemia , 2008, British journal of haematology.

[6]  B. Williams,et al.  Mapping and quantifying mammalian transcriptomes by RNA-Seq , 2008, Nature Methods.

[7]  M. Saha,et al.  Pharmacological activation of the p53 pathway in haematological malignancies , 2009, Journal of Clinical Pathology.

[8]  G. Smyth,et al.  ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. , 2009, Journal of immunological methods.

[9]  J. Downing,et al.  Mouse models of human AML accurately predict chemotherapy response. , 2009, Genes & development.

[10]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[11]  C. Deisenroth,et al.  Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway , 2010, Oncogene.

[12]  F. Boisvert,et al.  The Nucleolus under Stress , 2010, Molecular Cell.

[13]  S. Lowe,et al.  p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. , 2010, Genes & development.

[14]  R. Hannan,et al.  Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. , 2011, Cancer research.

[15]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[16]  Mark A. Dawson,et al.  Inhibition of BET Recruitment to Chromatin As An Effective Treatment for MLL-Fusion Leukaemia , 2011 .

[17]  Yonghong Xiao,et al.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.

[18]  J. Hess,et al.  The pathogenesis of mixed-lineage leukemia. , 2012, Annual review of pathology.

[19]  Carleen Cullinane,et al.  Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. , 2012, Cancer cell.

[20]  Adam Siddiqui-Jain,et al.  Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics. , 2012, ACS medicinal chemistry letters.

[21]  Hanhui Ma,et al.  The nucleolus stress response is coupled to an ATR-Chk1–mediated G2 arrest , 2013, Molecular biology of the cell.

[22]  A. Iwama,et al.  Downregulation of rRNA Transcription Triggers Cell Differentiation , 2014, PloS one.

[23]  M. Asashima,et al.  Biosynthesis of Ribosomal RNA in Nucleoli Regulates Pluripotency and Differentiation Ability of Pluripotent Stem Cells , 2014, Stem cells.

[24]  C. Bieberich,et al.  A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. , 2014, Cancer cell.

[25]  T. Imamura,et al.  Sensitivity of MLL-rearranged AML cells to all-trans retinoic acid is associated with the level of H3K4me2 in the RARα promoter region , 2014, Blood Cancer Journal.

[26]  M. Buszczak,et al.  Changes in rRNA Transcription Influence Proliferation and Cell Fate Within a Stem Cell Lineage , 2014, Science.

[27]  H. Kantarjian,et al.  TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases , 2015, Journal of Hematology & Oncology.

[28]  Astrid S. Pfister,et al.  The Wnt Target Protein Peter Pan Defines a Novel p53-independent Nucleolar Stress-Response Pathway* , 2015, The Journal of Biological Chemistry.

[29]  Mark A. Dawson,et al.  BET inhibitor resistance emerges from leukaemia stem cells , 2015, Nature.

[30]  P. Brown,et al.  rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis , 2015, Oncotarget.

[31]  K. Khanna,et al.  Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling , 2016, Oncotarget.

[32]  Angel F. Lopez,et al.  Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia. , 2017, Blood.